

Thomas Dörner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5496294/publications.pdf>

Version: 2024-02-01

246
papers

25,276
citations

8755

75
h-index

7950

149
g-index

279
all docs

279
docs citations

279
times ranked

24966
citing authors

#	ARTICLE	IF	CITATIONS
1	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1400-1412.	5.6	1,098
2	Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. <i>Nature Reviews Rheumatology</i> , 2020, 16, 155-166.	8.0	952
3	Competence and competition: the challenge of becoming a long-lived plasma cell. <i>Nature Reviews Immunology</i> , 2006, 6, 741-750.	22.7	882
4	IL-35-producing B cells are critical regulators of immunity during autoimmune and infectious diseases. <i>Nature</i> , 2014, 507, 366-370.	27.8	882
5	Joint European League Against Rheumatism and European Renal Association "European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1771-1782.	0.9	868
6	Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). <i>European Journal of Immunology</i> , 2019, 49, 1457-1973.	2.9	766
7	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1151-1159.	0.9	759
8	EULAR recommendations for the management of antiphospholipid syndrome in adults. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1296-1304.	0.9	664
9	Disturbed Peripheral B Lymphocyte Homeostasis in Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2000, 165, 5970-5979.	0.8	564
10	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 958-967.	0.9	558
11	Guidelines for the use of flow cytometry and cell sorting in immunological studies [*] . <i>European Journal of Immunology</i> , 2017, 47, 1584-1797.	2.9	505
12	Immunopathogenic mechanisms of systemic autoimmune disease. <i>Lancet, The</i> , 2013, 382, 819-831.	13.7	446
13	Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. <i>Lancet, The</i> , 2018, 392, 222-231.	13.7	396
14	Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 909-920.	0.9	394
15	Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. <i>Blood</i> , 2005, 105, 1614-1621.	1.4	383
16	EULAR Sjögren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 968-972.	0.9	383
17	Novel paradigms in systemic lupus erythematosus. <i>Lancet, The</i> , 2019, 393, 2344-2358.	13.7	363
18	Correlation between circulating CD27 ^{high} plasma cells and disease activity in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2003, 48, 1332-1342.	6.7	319

#	ARTICLE	IF	CITATIONS
19	EULAR recommendations for the management of Sjögren's syndrome with topical and systemic therapies. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 3-18.	0.9	307
20	Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2006, 54, 2377-2386.	6.7	282
21	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 554-561.	0.9	268
22	Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2006, 8, R74.	3.5	267
23	Activated memory B cell subsets correlate with disease activity in systemic lupus erythematosus: Delineation by expression of CD27, IgD, and CD95. <i>Arthritis and Rheumatism</i> , 2008, 58, 1762-1773.	6.7	263
24	Emerging cell and cytokine targets in rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2014, 10, 77-88.	8.0	260
25	Antibodies and B Cell Memory in Viral Immunity. <i>Immunity</i> , 2007, 27, 384-392.	14.3	247
26	Memory B and memory plasma cells. <i>Immunological Reviews</i> , 2010, 237, 117-139.	6.0	242
27	Diminished peripheral blood memory B cells and accumulation of memory B cells in the salivary glands of patients with Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 2002, 46, 2160-2171.	6.7	241
28	Blood-borne human plasma cells in steady state are derived from mucosal immune responses. <i>Blood</i> , 2009, 113, 2461-2469.	1.4	230
29	EULAR Sjogren's syndrome disease activity index (ESSDAI): a user guide. <i>RMD Open</i> , 2015, 1, e000022-e000022.	3.8	229
30	Mechanisms of B cell autoimmunity in SLE. <i>Arthritis Research and Therapy</i> , 2011, 13, 243.	3.5	225
31	Defining disease activity states and clinically meaningful improvement in primary Sjögren's syndrome with EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 382-389.	0.9	225
32	Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients. <i>Science Immunology</i> , 2021, 6, eabj1031.	11.9	223
33	Characterization of systemic disease in primary Sjögren's syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. <i>Rheumatology</i> , 2015, 54, 2230-2238.	1.9	220
34	Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition). <i>European Journal of Immunology</i> , 2021, 51, 2708-3145.	2.9	198
35	Rheumatoid factor revisited. <i>Current Opinion in Rheumatology</i> , 2004, 16, 246-253.	4.3	193
36	Validation of EULAR primary Sjögren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 859-866.	0.9	193

#	ARTICLE	IF	CITATIONS
37	LAG-3 Inhibitory Receptor Expression Identifies Immunosuppressive Natural Regulatory Plasma Cells. <i>Immunity</i> , 2018, 49, 120-133.e9.	14.3	190
38	Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2004, 50, 3211-3220.	6.7	179
39	Plasma cell differentiation and survival. <i>Current Opinion in Immunology</i> , 2008, 20, 162-169.	5.5	178
40	Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 165-174.	0.9	173
41	Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID). <i>Arthritis Research and Therapy</i> , 2011, 13, R75.	3.5	170
42	A unique population of IgG-expressing plasma cells lacking CD19 is enriched in human bone marrow. <i>Blood</i> , 2015, 125, 1739-1748.	1.4	170
43	Anti-CD20 therapy in patients with rheumatoid arthritis: Predictors of response and B cell subset regeneration after repeated treatment. <i>Arthritis and Rheumatism</i> , 2008, 58, 1566-1575.	6.7	167
44	The role of biosimilars in the treatment of rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 322-328.	0.9	166
45	The changing landscape of biosimilars in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 974-982.	0.9	160
46	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 71-87.	0.9	158
47	B-cell-directed therapies for autoimmune disease. <i>Nature Reviews Rheumatology</i> , 2009, 5, 433-441.	8.0	152
48	SARS-CoV-2 in severe COVID-19 induces a TGF- β -dominated chronic immune response that does not target itself. <i>Nature Communications</i> , 2021, 12, 1961.	12.8	145
49	Toll-like receptor signalling in B cells during systemic lupus erythematosus. <i>Nature Reviews Rheumatology</i> , 2021, 17, 98-108.	8.0	143
50	A serologic marker for fetal risk of congenital heart block. <i>Arthritis and Rheumatism</i> , 2002, 46, 1233-1241.	6.7	135
51	The role of B cells in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2003, 15, 246-252.	4.3	133
52	B cells in autoimmunity. <i>Arthritis Research and Therapy</i> , 2009, 11, 247.	3.5	130
53	Performance of Antinuclear Antibodies for Classifying Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Regression of Diagnostic Data. <i>Arthritis Care and Research</i> , 2018, 70, 428-438.	3.4	129
54	B cells in Sjögren's syndrome: indications for disturbed selection and differentiation in ectopic lymphoid tissue. <i>Arthritis Research and Therapy</i> , 2007, 9, 218.	3.5	124

#	ARTICLE	IF	CITATIONS
55	Early diagnosis of primary Sjögren's syndrome: EULAR-SS task force clinical recommendations. Expert Review of Clinical Immunology, 2016, 12, 137-156.	3.0	118
56	Somatic hypermutation of human immunoglobulin heavy chain genes: targeting of RGYW motifs on both DNA strands. European Journal of Immunology, 1998, 28, 3384-3396.	2.9	117
57	Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2012: Table 1. Annals of the Rheumatic Diseases, 2013, 72, ii2-ii34.	0.9	114
58	Treatment of primary Sjögren's syndrome with ivalumab (VAY736) targeting B cells by BAFF receptor blockade coupled with enhanced, antibody-dependent cellular cytotoxicity. Annals of the Rheumatic Diseases, 2019, 78, 641-647.	0.9	113
59	Abnormalities of B cell subsets in patients with systemic lupus erythematosus. Journal of Immunological Methods, 2011, 363, 187-197.	1.4	111
60	Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Research and Therapy, 2005, 7, R1001.	3.5	110
61	Steady-state generation of mucosal IgA+ plasmablasts is not abrogated by B-cell depletion therapy with rituximab. Blood, 2010, 116, 5181-5190.	1.4	107
62	High-level serum B-cell activating factor and promoter polymorphisms in patients with idiopathic thrombocytopenic purpura. British Journal of Haematology, 2007, 136, 309-314.	2.5	105
63	Abnormalities in peripheral B cell memory of patients with primary Sjögren's syndrome. Arthritis and Rheumatism, 2004, 50, 1897-1908.	6.7	99
64	Immunopathogenesis of primary Sjögren's syndrome: implications for disease management and therapy. Current Opinion in Rheumatology, 2005, 17, 558-565.	4.3	98
65	Repeated administration of dapirolizumab pegol in a randomised phase I study is well tolerated and accompanied by improvements in several composite measures of systemic lupus erythematosus disease activity and changes in whole blood transcriptomic profiles. Annals of the Rheumatic Diseases, 2017, 76, 1837-1844.	0.9	97
66	2021 DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Science and Medicine, 2021, 8, e000538.	2.7	97
67	Biosimilars in rheumatology: current perspectives and lessons learnt. Nature Reviews Rheumatology, 2015, 11, 713-724.	8.0	96
68	Analysis of the targeting of the hypermutational machinery and the impact of subsequent selection on the distribution of nucleotide changes in human V rearrangements. Immunological Reviews, 1998, 162, 161-171.	6.0	95
69	Targeting B cells in immune-mediated inflammatory disease: A comprehensive review of mechanisms of action and identification of biomarkers. , 2010, 125, 464-475.		93
70	How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria. Arthritis and Rheumatology, 2019, 71, 91-98.	5.6	93
71	Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration. Arthritis Care and Research, 2018, 70, 571-581.	3.4	91
72	In vivo effects of the anti-interleukin-6 receptor inhibitor tocilizumab on the B cell compartment. Arthritis and Rheumatism, 2011, 63, 1255-1264.	6.7	87

#	ARTICLE	IF	CITATIONS
73	Epratuzumab targeting of CD22 affects adhesion molecule expression and migration of B-cells in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2010, 12, R204.	3.5	86
74	Tissue Distribution and Dependence of Responsiveness of Human Antigen-Specific Memory B Cells. <i>Journal of Immunology</i> , 2014, 192, 3091-3100.	0.8	83
75	New approaches of B-cell-directed therapy: beyond rituximab. <i>Current Opinion in Rheumatology</i> , 2008, 20, 263-268.	4.3	82
76	B and T Cell Responses after a Third Dose of SARS-CoV-2 Vaccine in Kidney Transplant Recipients. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 3027-3033.	6.1	82
77	Switching Between Reference Biologics and Biosimilars for the Treatment of Rheumatology, Gastroenterology, and Dermatology Inflammatory Conditions: Considerations for the Clinician. <i>Current Rheumatology Reports</i> , 2017, 19, 37.	4.7	79
78	Vaccine-Induced Thrombocytopenia with Severe Headache. <i>New England Journal of Medicine</i> , 2021, 385, 2103-2105.	27.0	79
79	Secondary Immunization Generates Clonally Related Antigen-Specific Plasma Cells and Memory B Cells. <i>Journal of Immunology</i> , 2010, 185, 3103-3110.	0.8	78
80	Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity. <i>Arthritis Research and Therapy</i> , 2012, 14, S1.	3.5	78
81	Thromboembolic complications in critically ill COVID-19 patients are associated with impaired fibrinolysis. <i>Critical Care</i> , 2020, 24, 676.	5.8	78
82	Outcome measures for primary Sjögren's syndrome: A comprehensive review. <i>Journal of Autoimmunity</i> , 2014, 51, 51-56.	6.5	77
83	Adaptation of humoral memory. <i>Immunological Reviews</i> , 2006, 211, 295-302.	6.0	73
84	Safety and efficacy of subcutaneous ianalumab (VAY736) in patients with primary Sjögren's syndrome: a randomised, double-blind, placebo-controlled, phase 2b dose-finding trial. <i>Lancet, The</i> , 2022, 399, 161-171.	13.7	72
85	Dysregulation of chemokine receptor expression and function by B cells of patients with primary Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 2005, 52, 2109-2119.	6.7	70
86	CD22 ligation inhibits downstream B cell receptor signaling and Ca ²⁺ flux upon activation. <i>Arthritis and Rheumatism</i> , 2013, 65, 770-779.	6.7	70
87	Beyond pan-B-cell-directed therapy – new avenues and insights into the pathogenesis of SLE. <i>Nature Reviews Rheumatology</i> , 2016, 12, 645-657.	8.0	69
88	New concepts in the pathogenesis of Sjögren syndrome: many questions, fewer answers. <i>Current Opinion in Rheumatology</i> , 2003, 15, 563-570.	4.3	64
89	Immunopathologic role of B lymphocytes in rheumatoid arthritis: Rationale of B cell-directed therapy. <i>Autoimmunity Reviews</i> , 2006, 5, 437-442.	5.8	63
90	Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2009, 9, 82-89.	5.8	62

#	ARTICLE	IF	CITATIONS
91	Temporary antimetabolite treatment hold boosts SARS-CoV-2 vaccination-specific humoral and cellular immunity in kidney transplant recipients. JCI Insight, 2022, 7, .	5.0	62
92	Autoantibodies in primary Sjögren's syndrome are directed against proteasomal subunits of the β and γ type. Arthritis and Rheumatism, 1999, 42, 697-702.	6.7	60
93	Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria. Arthritis Care and Research, 2021, 73, 1490-1501.	3.4	60
94	The mechanistic impact of CD22 engagement with epratuzumab on B cell function: Implications for the treatment of systemic lupus erythematosus. Autoimmunity Reviews, 2015, 14, 1079-1086.	5.8	59
95	Increased Frequency of a Unique Spleen Tyrosine Kinase Bright Memory B Cell Population in Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2014, 66, 3424-3435.	5.6	58
96	Crossroads of B cell activation in autoimmunity: rationale of targeting B cells. Journal of rheumatology Supplement, The, 2006, 77, 3-11.	2.2	58
97	Development of the ClinESSDAI: a clinical score without biological domain. A tool for biological studies. Annals of the Rheumatic Diseases, 2016, 75, 1945-1950.	0.9	57
98	Role of the spleen in peripheral memory B-cell homeostasis in patients with autoimmune thrombocytopenia purpura. Clinical Immunology, 2009, 130, 199-212.	3.2	56
99	CD27-IgD- memory B cells are modulated by in vivo interleukin-6 receptor (IL-6R) blockade in rheumatoid arthritis. Arthritis Research and Therapy, 2015, 17, 61.	3.5	56
100	Treatment of Sjögren's syndrome: current therapy and future directions. Rheumatology, 2021, 60, 2066-2074.	1.9	55
101	B Cell Numbers Predict Humoral and Cellular Response Upon SARS-CoV-2 Vaccination Among Patients Treated With Rituximab. Arthritis and Rheumatology, 2022, 74, 934-947.	5.6	55
102	Aberrant Activation of B Cells in Patients with Rheumatoid Arthritis. Annals of the New York Academy of Sciences, 2003, 987, 246-248.	3.8	54
103	Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjögren's syndrome. RMD Open, 2019, 5, e001064.	3.8	53
104	Immunogenicity of COVID-19 Tozinameran Vaccination in Patients on Chronic Dialysis. Frontiers in Immunology, 2021, 12, 690698.	4.8	52
105	Off-label use of rituximab for systemic lupus erythematosus in Europe. Lupus Science and Medicine, 2016, 3, e000163.	2.7	51
106	Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 634-640.	0.9	51
107	Are interferon-related biomarkers advantageous for monitoring disease activity in systemic lupus erythematosus? A longitudinal benchmark study. Rheumatology, 2017, 56, 1618-1626.	1.9	49
108	Efficacy of Epratuzumab, an Anti-CD22 Monoclonal IgG Antibody, in Systemic Lupus Erythematosus Patients With Associated Sjögren's Syndrome. Arthritis and Rheumatology, 2018, 70, 763-773.	5.6	49

#	ARTICLE	IF	CITATIONS
109	Somatic hypermutation of V λ J λ rearrangements: targeting of RGYW motifs on both DNA strands and preferential selection of mutated codons within RGYW motifs. <i>European Journal of Immunology</i> , 1999, 29, 4011-4021.	2.9	48
110	Coagulation and the fibrin network in rheumatic disease: a role beyond haemostasis. <i>Nature Reviews Rheumatology</i> , 2012, 8, 738-746.	8.0	48
111	Multicenter Delphi Exercise to Identify Important Key Items for Classifying Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2018, 70, 1488-1494.	3.4	48
112	Phase 2, randomized, placebo-controlled trial of dapirolizumab pegol in patients with moderate-to-severe active systemic lupus erythematosus. <i>Rheumatology</i> , 2021, 60, 5397-5407.	1.9	48
113	Phase 2 Trial of Iberdomide in Systemic Lupus Erythematosus. <i>New England Journal of Medicine</i> , 2022, 386, 1034-1045.	27.0	48
114	Active systemic lupus erythematosus is associated with a reduced cytokine production by B cells in response to TLR9 stimulation. <i>Arthritis Research and Therapy</i> , 2014, 16, 477.	3.5	47
115	Response to: "2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus" by Aringer et al. by Cui et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e166-e166.	0.9	47
116	Significantly Increased Maternal and Fetal IgG autoantibody levels to 52kD Ro(SS-A) and La(SS-B) in Complete Congenital Heart Block. <i>Journal of Autoimmunity</i> , 1995, 8, 675-684.	6.5	46
117	Regeneration of the immunoglobulin heavy-chain repertoire after transient B-cell depletion with an anti-CD20 antibody. <i>Arthritis Research</i> , 2005, 7, R714.	2.0	46
118	Epratuzumab inhibits the production of the proinflammatory cytokines IL-6 and TNF- α , but not the regulatory cytokine IL-10, by B cells from healthy donors and SLE patients. <i>Arthritis Research and Therapy</i> , 2015, 17, 185.	3.5	46
119	Chronic lymphocytic leukemia preceded by cold agglutinin disease: intracлонаl immunoglobulin light-chain diversity in VH4-34 expressing single leukemic B cells. <i>Blood</i> , 2002, 100, 3419-3422.	1.4	45
120	Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. <i>Journal of Rheumatology</i> , 2019, 46, 721-726.	2.0	45
121	Immunoglobulin variable-region gene usage in systemic autoimmune diseases. <i>Arthritis and Rheumatism</i> , 2001, 44, 2715-2727.	6.7	43
122	CD22 and Autoimmune Disease. <i>International Reviews of Immunology</i> , 2012, 31, 363-378.	3.3	43
123	High maternal expression of SIGLEC1 on monocytes as a surrogate marker of a type I interferon signature is a risk factor for the development of autoimmune congenital heart block. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1476-1480.	0.9	43
124	SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sjögren's syndrome. <i>RMD Open</i> , 2016, 2, e000292.	3.8	42
125	Identification and Characterization of Post-activated B Cells in Systemic Autoimmune Diseases. <i>Frontiers in Immunology</i> , 2019, 10, 2136.	4.8	41
126	Enhanced Mutational Activity of V λ Gene Rearrangements in Systemic Lupus Erythematosus. <i>Clinical Immunology</i> , 1999, 92, 188-196.	3.2	40

#	ARTICLE	IF	CITATIONS
127	Abnormalities of B cell phenotype, immunoglobulin gene expression and the emergence of autoimmunity in Sjögren's syndrome. <i>Arthritis Research</i> , 2002, 4, 360.	2.0	40
128	B cells. <i>Current Opinion in Rheumatology</i> , 2014, 26, 228-236.	4.3	40
129	Enhanced Tyrosine Phosphatase Activity Underlies Dysregulated B-cell Receptor Signaling and Promotes Survival of Human Lupus B-cells. <i>Arthritis and Rheumatology</i> , 2015, 68, n/a-n/a.	5.6	40
130	Antiphospholipid antibody profiling – Time for a new technical approach?. <i>Autoimmunity Reviews</i> , 2012, 11, 821-826.	5.8	39
131	Targeting B Cells and Plasma Cells in Glomerular Diseases: Translational Perspectives. <i>Journal of the American Society of Nephrology: JASN</i> , 2018, 29, 741-758.	6.1	39
132	Deep Phenotyping of CD11c+ B Cells in Systemic Autoimmunity and Controls. <i>Frontiers in Immunology</i> , 2021, 12, 635615.	4.8	39
133	Impact of IL-6 receptor inhibition on human memory B cells in vivo: impaired somatic hypermutation in pre-switch memory B cells and modulation of mutational targeting in memory B cells. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1507-1510.	0.9	38
134	Antiphospholipid syndrome: state of the art on clinical practice guidelines. <i>RMD Open</i> , 2018, 4, e000785.	3.8	38
135	Delayed acquisition of somatic hypermutations in repopulated IGD+CD27+ memory B cell receptors after rituximab treatment. <i>Arthritis and Rheumatism</i> , 2009, 60, 2284-2293.	6.7	37
136	Drivers of the immunopathogenesis in systemic lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2017, 31, 321-333.	3.3	37
137	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 775-781.	0.9	37
138	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research. <i>RMD Open</i> , 2020, 6, e001374.	3.8	36
139	Selecting B cells and plasma cells to memory. <i>Journal of Experimental Medicine</i> , 2005, 201, 497-499.	8.5	35
140	Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways. <i>Lupus Science and Medicine</i> , 2020, 7, e000424.	2.7	35
141	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1333-1339.	0.9	35
142	Single-step autoantibody profiling in antiphospholipid syndrome using a multi-line dot assay. <i>Arthritis Research and Therapy</i> , 2011, 13, R118.	3.5	34
143	Comparable impact of mutational and selective influences in shaping the expressed repertoire of peripheral IgM+/CD5 ^{hi} and IgM+/CD5 ^{lo} B cells. <i>European Journal of Immunology</i> , 1998, 28, 657-668.	2.9	33
144	Altered increase in STAT1 expression and phosphorylation in severe COVID-19. <i>European Journal of Immunology</i> , 2022, 52, 138-148.	2.9	33

#	ARTICLE	IF	CITATIONS
145	Immunoglobulin repertoire analysis provides new insights into the immunopathogenesis of Sjögren's syndrome. <i>Autoimmunity Reviews</i> , 2002, 1, 119-124.	5.8	32
146	B-cell targeting: a novel approach to immune intervention today and tomorrow. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 1287-1299.	3.1	32
147	Significance of Autoantibodies in Neonatal Lupus Erythematosus. <i>International Archives of Allergy and Immunology</i> , 2000, 123, 58-66.	2.1	31
148	Targeting and selection of mutations in human V λ rearrangements. <i>European Journal of Immunology</i> , 2000, 30, 1597-1605.	2.9	31
149	Molecular basis of immunoglobulin variable region gene usage in systemic autoimmunity. <i>Clinical and Experimental Medicine</i> , 2005, 4, 159-169.	3.6	30
150	Anticytokine therapy impacting on B cells in autoimmune diseases. <i>Current Opinion in Rheumatology</i> , 2009, 21, 205-210.	4.3	30
151	What do we know about memory B cells in primary Sjögren's syndrome?. <i>Autoimmunity Reviews</i> , 2010, 9, 600-603.	5.8	28
152	Current aspects of anti-CD20 therapy in rheumatoid arthritis. <i>Current Opinion in Pharmacology</i> , 2010, 10, 316-321.	3.5	28
153	Plasmablasts With a Mucosal Phenotype Contribute to Plasmacytosis in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2017, 69, 2018-2028.	5.6	28
154	Response to: "European League against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus: the laboratory immunologist's point of view" by Infantino et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e189-e189.	0.9	28
155	Associations Between Classification Criteria Items in Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2020, 72, 1820-1826.	3.4	28
156	Targeting CD22 as a strategy for treating systemic autoimmune diseases. <i>Therapeutics and Clinical Risk Management</i> , 2007, 3, 953-9.	2.0	28
157	Targeting and subsequent selection of somatic hypermutations in the human V λ repertoire. <i>European Journal of Immunology</i> , 1999, 29, 3122-3132.	2.9	27
158	Pathogenic memory plasma cells in autoimmunity. <i>Current Opinion in Immunology</i> , 2019, 61, 86-91.	5.5	26
159	The influence of CD40-CD154 interactions on the expressed human VH repertoire: analysis of VH genes expressed by individual B cells of a patient with X-linked hyper-IgM syndrome. <i>International Immunology</i> , 2000, 12, 767-775.	4.0	25
160	Implant-related inflammatory arthritis. <i>Nature Clinical Practice Rheumatology</i> , 2006, 2, 53-56.	3.2	25
161	Deciphering the role of NETs and networks in SLE. <i>Nature Reviews Rheumatology</i> , 2012, 8, 68-70.	8.0	25
162	Enhanced Programmed Death 1 and Diminished Programmed Death Ligand 1 Upregulation Capacity of Post-Activated Lupus B Cells. <i>Arthritis and Rheumatology</i> , 2019, 71, 1539-1544.	5.6	25

#	ARTICLE	IF	CITATIONS
163	Similar characteristics of the CDR3 of VH 1-69/DP-10 rearrangements in normal human peripheral blood and chronic lymphocytic leukaemia B cells. <i>British Journal of Haematology</i> , 1998, 102, 516-521.	2.5	24
164	Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1556-1563.	0.9	24
165	Elevated STAT1 expression but not phosphorylation in lupus B cells correlates with disease activity and increased plasmablast susceptibility. <i>Rheumatology</i> , 2020, 59, 3435-3442.	1.9	23
166	Immunoglobulin V λ light chain gene usage in patients with Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 2001, 44, 2620-2632.	6.7	22
167	Expression of Proteasomal Immunosubunit β 1i Is Dysregulated in Inflammatory Infiltrates of Minor Salivary Glands in Sjögren's Syndrome. <i>Journal of Rheumatology</i> , 2009, 36, 2694-2703.	2.0	22
168	Detection of Autoantibodies to Ro(SS-A), La(SS-B) and U1RNP in Different Congenital Heart Rhythm Disorders Using Immunoblot and Enzyme Immunoassay. <i>Journal of Autoimmunity</i> , 1994, 7, 93-106.	6.5	21
169	Enhanced Mutational Activity and Disturbed Selection of Mutations in V κ Gene Rearrangements in a Patient with Systemic Lupus Erythematosus. <i>Autoimmunity</i> , 2001, 33, 61-76.	2.6	21
170	Immunoglobulin V λ light chain gene analysis in patients with Sjögren's syndrome. <i>Arthritis and Rheumatism</i> , 2001, 44, 626-637.	6.7	21
171	Postactivated B cells in systemic lupus erythematosus: update on translational aspects and therapeutic considerations. <i>Current Opinion in Rheumatology</i> , 2019, 31, 175-184.	4.3	20
172	Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial. <i>Arthritis Research and Therapy</i> , 2022, 24, 112.	3.5	19
173	Editorial Overview: Antinuclear Antibody- and Extractable Nuclear Antigen-Related Diseases. <i>International Archives of Allergy and Immunology</i> , 2000, 123, 5-9.	2.1	18
174	Simultaneous Presence of Non- and Highly Mutated Keyhole Limpet Hemocyanin (KLH)-Specific Plasmablasts Early after Primary KLH Immunization Suggests Cross-Reactive Memory B Cell Activation. <i>Journal of Immunology</i> , 2018, 200, 3981-3992.	0.8	18
175	Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1267-1272.	0.9	18
176	Efficacy and safety of tabalumab, an anti-BAFF monoclonal antibody, in patients with moderate-to-severe rheumatoid arthritis and inadequate response to TNF inhibitors: results of a randomised, double-blind, placebo-controlled, phase 3 study. <i>RMD Open</i> , 2015, 1, e000037.	3.8	17
177	B cells in systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2022, 34, 125-132.	4.3	17
178	Early and Rapid Identification of COVID-19 Patients with Neutralizing Type I Interferon Auto-antibodies. <i>Journal of Clinical Immunology</i> , 2022, 42, 1111-1129.	3.8	17
179	Physician Global Assessment International Standardisation CONsensus in Systemic Lupus Erythematosus: the PISCOS study. <i>Lancet Rheumatology</i> , The, 2022, 4, e441-e449.	3.9	17
180	Global consensus building and prioritisation of fundamental lupus challenges: the ALPHA project. <i>Lupus Science and Medicine</i> , 2019, 6, e000342.	2.7	15

#	ARTICLE	IF	CITATIONS
181	Perturbations in the impact of mutational activity on Vlambda genes in systemic lupus erythematosus. <i>Arthritis Research</i> , 2001, 3, 368.	2.0	14
182	Engagement of CD22 on B cells with the monoclonal antibody epratuzumab stimulates the phosphorylation of upstream inhibitory signals of the B cell receptor. <i>Journal of Cell Communication and Signaling</i> , 2016, 10, 143-151.	3.4	14
183	Human CD27+ memory B cells colonize a superficial follicular zone in the palatine tonsils with similarities to the spleen. A multicolor immunofluorescence study of lymphoid tissue. <i>PLoS ONE</i> , 2020, 15, e0229778.	2.5	14
184	Therapeutic Cytokine Inhibition Modulates Activation and Homing Receptors of Peripheral Memory B Cell Subsets in Rheumatoid Arthritis Patients. <i>Frontiers in Immunology</i> , 2020, 11, 572475.	4.8	13
185	Biological impact of iberdomide in patients with active systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1136-1142.	0.9	13
186	BTLA Expression and Function Are Impaired on SLE B Cells. <i>Frontiers in Immunology</i> , 2021, 12, 667991.	4.8	12
187	Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects. <i>RMD Open</i> , 2021, 7, e001637.	3.8	12
188	Autoantibodies in normals--the value of predicting rheumatoid arthritis. <i>Arthritis Research</i> , 2004, 6, 282.	2.0	11
189	Advances in SLE classification criteria. <i>Journal of Autoimmunity</i> , 2022, 132, 102845.	6.5	11
190	Smaller role for pol I?. <i>Nature Immunology</i> , 2001, 2, 982-983.	14.5	10
191	Biomarkers as tools for improved diagnostic and therapeutic monitoring in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2009, 11, 255.	3.5	10
192	Restrictive IgG antibody response against mutated citrullinated vimentin predicts response to rituximab in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 206.	3.5	10
193	Anti-Interleukin-6 signalling therapy rebalances the disrupted cytokine production of B cells from patients with active rheumatoid arthritis. <i>European Journal of Immunology</i> , 2018, 48, 194-203.	2.9	10
194	Circulating Pentraxin3-Specific B Cells Are Decreased in Lupus Nephritis. <i>Frontiers in Immunology</i> , 2019, 10, 29.	4.8	10
195	Therapeutic implications of the anergic/postactivated status of B cells in systemic lupus erythematosus. <i>RMD Open</i> , 2020, 6, e001258.	3.8	10
196	Plasmablast-like Phenotype Among Antigen-Experienced CXCR5 ⁺ CD19 ^{low} B Cells in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2022, 74, 1556-1568.	5.6	10
197	Immune checkpoints and the multiple faces of B cells in systemic lupus erythematosus. <i>Current Opinion in Rheumatology</i> , 2021, 33, 592-597.	4.3	9
198	Phenotypic Analysis of B-Cells and Plasma Cells. <i>Methods in Molecular Medicine</i> , 2007, 136, 3-18.	0.8	9

#	ARTICLE	IF	CITATIONS
199	Long-term repopulation of peripheral B-cell subsets after single and repeated rituximab infusions in patients with rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, 347-53.	0.8	9
200	A Narrative Literature Review Comparing the Key Features of Musculoskeletal Involvement in Rheumatoid Arthritis and Systemic Lupus Erythematosus. <i>Rheumatology and Therapy</i> , 2022, 9, 781-802.	2.3	9
201	CD39 and CD326 Are Bona Fide Markers of Murine and Human Plasma Cells and Identify a Bone Marrow Specific Plasma Cell Subpopulation in Lupus. <i>Frontiers in Immunology</i> , 2022, 13, 873217.	4.8	9
202	Antibodies against protein Z and fetal loss: current perspectives. <i>Clinical and Experimental Medicine</i> , 2005, 5, 50-54.	3.6	8
203	Current and future treatment in primary Sjögren's syndrome—still challenging development. <i>Joint Bone Spine</i> , 2022, 89, 105406.	1.6	8
204	Cryopreserved Human B Cells as an Alternative Source for Single Cell mRNA Analysis. <i>Cell and Tissue Banking</i> , 2005, 6, 299-308.	1.1	7
205	Clinical trial and "real-world" data support switching from a bio-originator to its biosimilar. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e44-e44.	0.9	7
206	Lessons from tofacitinib in patients with cardiovascular risk factors: increased pulmonary embolism or isolated (thrombotic) pulmonary occlusion rates?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1389-1392.	0.9	7
207	Role for antimalarials in the management of COVID-19. <i>Current Opinion in Rheumatology</i> , 2020, 32, 449-457.	4.3	7
208	Human IgA-Expressing Bone Marrow Plasma Cells Characteristically Upregulate Programmed Cell Death Protein-1 Upon B Cell Receptor Stimulation. <i>Frontiers in Immunology</i> , 2020, 11, 628923.	4.8	7
209	The ALPHA Project: Establishing consensus and prioritisation of global community recommendations to address major challenges in lupus diagnosis, care, treatment and research. <i>Lupus Science and Medicine</i> , 2021, 8, e000433.	2.7	7
210	Addressing the clinical unmet needs in primary Sjögren's Syndrome through the sharing, harmonization and federated analysis of 21 European cohorts. <i>Computational and Structural Biotechnology Journal</i> , 2022, 20, 471-484.	4.1	7
211	B Cell Characteristics at Baseline Predict Vaccination Response in RTX Treated Patients. <i>Frontiers in Immunology</i> , 2022, 13, 822885.	4.8	7
212	Response to: Correspondence on "European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance" by Bossuyt et al. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e194-e194.	0.9	6
213	Resident memory CD4 ⁺ T lymphocytes mobilize from bone marrow to contribute to a systemic secondary immune reaction. <i>European Journal of Immunology</i> , 2022, 52, 737-752.	2.9	6
214	Development of systemic lupus erythematosus in a patient with congenital heart block. <i>Arthritis and Rheumatism</i> , 2003, 48, 2697-2698.	6.7	5
215	Viscoelastic testing reveals normalization of the coagulation profile 12 weeks after severe COVID-19. <i>Scientific Reports</i> , 2021, 11, 13325.	3.3	5
216	Evaluation of SIGLEC1 in the diagnosis of suspected systemic lupus erythematosus. <i>Rheumatology</i> , 2022, 61, 3396-3400.	1.9	5

#	ARTICLE	IF	CITATIONS
217	B- and Plasma Cell Subsets in Autoimmune Diseases: Translational Perspectives. <i>Journal of Investigative Dermatology</i> , 2022, 142, 811-822.	0.7	5
218	Difference between SLE classification and diagnosis and importance of attribution. Response to: "Do the 2019 EULAR/ACR SLE classification criteria close the door on certain groups of SLE patients?" by Chi et al. <i>Annals of the Rheumatic Diseases</i> , 2019, , annrheumdis-2019-216338.	0.9	4
219	Therapeutic Recommendations for the Management of Older Adult Patients with Sjögren's Syndrome. <i>Drugs and Aging</i> , 2021, 38, 265-284.	2.7	4
220	Motor and cognitive fatigue in SLE is associated with mood and health-related quality of life (HRQoL) in patients with SLE: results from the Patient Reported Outcomes in Lupus (PRO-Lupus) study. <i>Rheumatology</i> , 2018, 57, .	1.9	3
221	Response to: "New 2019 SLE EULAR/ACR classification criteria are valid for identifying patients with SLE among patients admitted for pericardial effusion" by Sacre et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e191-e191.	0.9	3
222	Response to: "Do 2019 European League against rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus also indicate the disease activity?" by Teng et al. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, e23-e23.	0.9	3
223	Ianalumab (VAY736) in primary Sjögren's syndrome: assessing disease activity using multi-modal ultrasound. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 126, 228-236.	0.8	3
224	B cell subset distribution in human bone marrow is stable and similar in left and right femur: An instructive case. <i>PLoS ONE</i> , 2019, 14, e0212525.	2.5	2
225	Reply. <i>Arthritis Care and Research</i> , 2019, 71, 696-697.	3.4	2
226	EZH2 Inhibition in B Cell Subsets: Comment on the Article by Rohraff et al. <i>Arthritis and Rheumatology</i> , 2020, 72, 371-373.	5.6	2
227	The Role of B Cells in Rheumatoid Arthritis. , 2009, , 97-106.		1
228	Response to: "New 2019 SLE EULAR/ACR classification criteria are valuable for distinguishing patients with SLE from patients with pSS" by Assan et al. <i>Annals of the Rheumatic Diseases</i> , 2019, , annrheumdis-2019-216250.	0.9	1
229	Reply. <i>Arthritis and Rheumatology</i> , 2020, 72, 695-696.	5.6	1
230	B cells in SLE. , 2021, , 131-138.		1
231	Somatic hypermutation of human immunoglobulin heavy chain genes: targeting of RGYW motifs on both DNA strands. <i>European Journal of Immunology</i> , 1998, 28, 3384-3396.	2.9	1
232	Response to: "Role of ANA testing in the classification of patients with systemic lupus erythematosus" by Pisetsky et al. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e125-e125.	0.9	1
233	Early and late responses in patients with rheumatoid arthritis who were conventional synthetic disease-modifying anti-rheumatic drug inadequate responders and were treated with tocilizumab or switched to rituximab: an open-label phase 3 trial (MIRAI). <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 937-945.	0.8	1
234	Contribution of B Cells to Autoimmune Pathogenesis. , 2006, , 461-501.		0

#	ARTICLE	IF	CITATIONS
235	Considering biosimilar policy. Considerations in Medicine, 2017, 1, 19-24.	0.0	0
236	7 Neonatale Lupussyndrome. , 2017, , .		0
237	Response to: "Development and initial validation of diagnostic gene signatures for systemic lupus erythematosus"™ by Wang et al. Annals of the Rheumatic Diseases, 2019, 80, annrheumdis-2019-216807.	0.9	0
238	09"Novel intracellular pathways. , 2020, , .		0
239	04"Baricitinib-induced changes in STAT-associated gene expression in systemic lupus erythematosus. , 2020, , .		0
240	08"Performance of the EULAR/ACR 2019 classification criteria for systemic lupus erythematosus in men, ethnicities, and early disease. , 2020, , .		0
241	Reply. Arthritis and Rheumatology, 2020, 72, 860-861.	5.6	0
242	Reply. Arthritis and Rheumatology, 2020, 72, 1404-1404.	5.6	0
243	27"Translational insights into the pathogenesis transforming SLE treatment. , 2021, , .		0
244	POS0692"IANALUMAB (VAY736) SAFETY AND EFFICACY IN PATIENTS WITH SJOGREN"™S SYNDROME: 52 WEEK RESULTS FROM A RANDOMISED, PLACEBO-CONTROLLED, PHASE 2B DOSE-RANGING TRIAL. Annals of the Rheumatic Diseases, 2021, 80, 593-594.	0.9	0
245	Mobilization of Tissue-Resident Memory CD4+ T Lymphocytes and Their Contribution to a Systemic Secondary Immune Reaction. SSRN Electronic Journal, 0, , .	0.4	0
246	1301"Effect of attribution on external validation of the EULAR/ACR SLE classification criteria. , 2021, , .		0